Several clinical trials in NSCLC have demonstrated a correlation between increased PD-L1 expression on NSCLC TC and/or tumor infiltrating IC with enhanced efficacy of anti- PD-1/PD-L1 immunotherapies [7, 8, 11–13]. Here, CD274 is linked to non-small cell lung carcinoma.